F ecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (rCDI), with cure rates higher than 80%. [1] [2] [3] FMT failure is defined as diarrhea and a positive stool laboratory test for C difficile at any point during the 8-week follow-up period after FMT. 4 However, this definition has 2 key limitations. First, there was a paucity of data suggesting the ideal followup period in rCDI after FMT. The current 8-week time point is arbitrary and was extrapolated from data treating CDI with antibiotics, and may not be applicable to FMT. Indeed, preliminary research has suggested that most failures may occur within 4 weeks, 5 highlighting an important clinical consideration. Understanding the timing of FMT failures is important in arranging ideal follow-up times after FMT. Second, patients who fail early after FMT may represent a different clinical phenotype compared with patients who fail late. There are a lack of data examining early vs late FMT failures. Further elucidation may lead to identification of risk factors for early FMT failure, allowing for earlier assessment, in-depth counseling, and potentially alternative treatments, such as long-term vancomycin or repeat FMT. Accordingly, we aimed to analyze time of FMT failure and evaluate patient characteristics for those with early vs late FMT failures.
Methods
This was a prospective cohort study of consecutive patients who underwent FMT by colonoscopy for rCDI between June 2013 and April 2015 at 2 tertiary referral centers. Patients were followed up for 8 weeks after FMT to assess for failure. Patients were assessed clinically and with stool testing at weeks 1, 4, and 8. Failure was defined as diarrheal symptoms (!3 unformed stools within a 24-hour period) 6 and a positive C difficile stool test by polymerase chain reaction for the presence of the toxin gene at any time point during the follow-up period. Patients contacted the study team between visits if diarrhea recurred. Treatment of the failure was at the investigators' discretion.
We developed a classification system anchored on follow-up evaluation at 1, 4, and 8 weeks after FMT. Primary nonresponders were defined as patients who experienced failure within the first week of FMT, including ongoing diarrhea after FMT. Early secondary nonresponders were defined as those who had an initial clinical response but then failed between weeks 1 and 4. Late secondary nonresponders were defined as patients who had an initial response but failed between weeks 4 and 8. The Kruskal-Wallis test for continuous variables and the Fisher exact test for categoric variables were used to compare failure categories.
Results
The final analysis included 167 patients. Overall, 28 (16.7%) experienced FMT failure. Among the failures, 7 were primary nonresponders (25%), 17 were early secondary nonresponders (61%), and 4 were late secondary nonresponders (14%), and 86% (24 of 28) had CDI recurrence by week 4. The mean failure time was 14.8 AE 12.5 days. There were no significant patient characteristic differences between groups (Table 1) . Among the 28 patients who failed FMT, 20 received repeat FMT, including 6 of the 7 primary nonresponders with 75% (15 of 20) resulting in CDI cure up to week 8. 
Discussion
FMT outcomes typically are assessed at 8 weeks after the procedure; however, this time point is not well supported. Here, we show that the majority of failures (86%) occur before week 4, with the mean failure time at 2 weeks after FMT, which is consistent with prior data. 5 Thus, clinicians should council patients to be particularly alert to symptoms of recurrent CDI in the first 4 weeks after FMT, even if symptoms initially have resolved.
In addition, we propose categorizing types of FMT failures to better assist clinicians. Overall, among FMT failures, 25% of patients had no response to FMT by week 1 (primary nonresponders). These patients may benefit from early repeat FMT. The majority of FMT failures (61%) occurred between weeks 1 and 4 (early secondary nonresponders) and there were relatively few patients who experienced failure after week 4 (late secondary nonresponders). Interestingly, these patients appeared similar clinically; however, these cohorts may have distinct microbial profiles, although sequencing data are needed to assess this hypothesis further.
Given these findings, we propose calling patients 1 week after FMT to assess for primary nonresponse in addition to counseling patients on when to be most alert to symptoms. Also, we recommend a telephone call or clinic assessment at week 4 to assess for early secondary nonresponse. The importance of the 4-week assessment is underscored by our finding that few failures occur after week 4. This follow-up protocol may help identify FMT failures earlier and in turn expedite treatment. IBD, inflammatory bowel disease.
